* Castle Biosciences Inc reported quarterly adjusted earnings of 8 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of nine analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -50 cents to 19 cents per share.

* Revenue rose 39.5% to $85.78 million from a year ago; analysts expected $79.84 million.

* Castle Biosciences Inc's reported EPS for the quarter was 8 cents​.

* The company reported quarterly net income of $2.27 million.

* Castle Biosciences Inc shares had risen by 18.0% this quarter and gained 55.9% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 77.7% in the last three months.​

* In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "strong buy"

Wall Street's median 12-month price target for Castle Biosciences Inc is 39.00 This summary was machine generated from LSEG data November 5 at 08:00 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.06 0.08 Beat

Jun. 30 2024 -0.27 0.31 Beat

Mar. 31 2024 -0.33 -0.09 Beat

Dec. 31 2023 -0.54 -0.10 Beat